Применение пробиотического штамма Streptococcus salivarius К12 в лечении острых тонзиллофарингитов у детей

Kramarov, S.О.; Yevtushenko, V.V.; Seryakova, I.Yu.; Kaminskaya, T.N.

doi:10.22141/2312-413x.8.3-4.2020.212657

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the action mode of salivaricins described previously, a well-maintained oropharynx homeostasis status also helps keeping the human host tolerant of respiratory tract infections. Previous studies have demonstrated that the use of oropharyngeal probiotic as part of the complex therapy of recurrent tonsillitis for 30 days was characterized by a rapid relief of both local and general manifestations of recurrent tonsillitis, as well as a significant improvement in the microflora of the upper respiratory tract ( Ilchenko et al, 2020 ; Kramarev et al, 2020 ). It is noted that in the control group, the incidence rate of respiratory tract infections increased linearly until the 20th day and seemed to slow down in the last 10 days during this trial, which may be explained by the fact that the number of hospitalized COVID-19 patients gradually decreased after they were cured and left the hospitals and the relief of COVID-19 pandemic in Wuhan area, thus relieved the shortage of medical resources during the emergence of the outbreak which caused extremely stressful work schedule and which also made the medical staff experience a lower immunity during the period of medical resource shortage.…”

Section: Discussionmentioning

confidence: 99%

Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study

Wang

Lin

Xiang

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Healthcare workers at the frontline are facing a substantial risk of respiratory tract infection during the COVID-19 outbreak due to an extremely stressful work schedule and public health event. A well-established first-line defense on oropharyngeal microbiome could be a promising strategy to protect individuals from respiratory tract infections including COVID-19. The most thoroughly studied oropharyngeal probiotic product which creates a stable upper respiratory tract microbiota capable of preventing upper respiratory tract infections was chosen to evaluate the safety and efficacy on reducing episodes of upper respiratory tract infections for COVID-19 healthcare workers. To our knowledge to date, this is the very first study describing the beneficial effects of oropharyngeal probiotic been administered by healthcare workers during the COVID-19 pandemic. In this randomized controlled trial, we provided the probiotics to frontline medical staff who work in the hospitals in Wuhan and had been in close contact with hospitalized COVID-19 patients for prophylactic use on a daily basis. Our finding suggests that oropharyngeal probiotic administration significantly reduced the incidence of respiratory tract infections by 64.8%, reduced the time experiencing respiratory tract infections and oral ulcer symptoms by 78%, shortened the days absent from work by 95.5%, and reduced the time under medication where there is no record of antibiotic and anti-viral drug intake in the probiotic group. Furthermore, medical staff treated with Bactoblis experienced sustained protection from respiratory tract infections since the 10th day of oropharyngeal probiotic administration resulting in an extremely low incidence rate of respiratory tract infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study

Wang

Lin

Xiang

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

Changes in the organs and tissues of the oral cavity in the new coronavirus infection (COVID-19): A review

2022

View full text Add to dashboard Cite

SARS-CoV-2 infection can cause changes in the organs and tissues of the oral cavity, which is associated with a wide distribution of angiotensin-converting enzyme type 2 in the oral cavity, mainly epithelial cells of the oral mucosa, gums and fibroblasts of the periodontal ligament. Thus, the oral mucosa is susceptible to SARS-CoV-2 infection and may act as a gateway for the virus, as well as a reservoir for SARS-CoV-2. We searched the literature for the period from the beginning of the pandemic until May 30, 2022, devoted to the study of changes in the organs and tissues of the oral cavity with a new coronavirus infection (COVID-19) in the electronic search engines PubMed/MEDLINE and Scopus. A special place in the study of changes in the organs and tissues of the oral cavity with a new coronavirus infection (COVID-19) is occupied by periodontal pathology. A number of reviews and clinical studies conclude the importance of good oral hygiene and periodontal health as an important aspect of COVID-19 prevention and management. Oral probiotics can be considered as a promising direction for correcting changes in organs and tissues of the oral cavity in COVID-19.

show abstract

Применение пробиотического штамма Streptococcus salivarius К12 в лечении острых тонзиллофарингитов у детей

Cited by 2 publications

References 14 publications

Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study

Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study

Changes in the organs and tissues of the oral cavity in the new coronavirus infection (COVID-19): A review

Contact Info

Product

Resources

About